Biblio Discovery — Demo Discovery Service

5 hasil untuk "A. Herman"

Menampilkan 1–5 · 1,10 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street

    Phillip James White; Robert W. McGarrah; Mark A. Herman dkk.

    Molecular Metabolism · 2021 · Inggris · OpenAlex Scopus

    BACKGROUND: A strong association of obesity and insulin resistance with increased circulating levels of branched-chain and aromatic amino acids and decreased glycine levels has been recognized in human subjects for decades. SCOPE OF REVIEW: More recently, human metabolomics and genetic studies have…

  2. Artikel Jurnal

    REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

    David M. Weinreich; Sumathi Sivapalasingam; Thomas D. Norton dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads. METHODS: In this ongoing, double-blind, phase 1-3 trial involving nonhospitalized patients with Covid-19, we investigated two fully human, neutralizing…

  3. Artikel Jurnal Teks lengkap

    The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

    Richard Copin; Alina Baum; Elzbieta H Wloga dkk.

    Cell · 2021 · Inggris · OpenAlex Scopus

    Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against…

  4. Artikel Jurnal

    Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

    Meagan P. O’Brien; Eduardo Forleo‐Neto; Bret J. Musser dkk.

    New England Journal of Medicine · 2021 · Inggris · OpenAlex Scopus

    BACKGROUND: REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV…